Duration of Chemotherapy for Metastatic Non–Small-Cell Lung Cancer: More May Be Better After All
- 10 July 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (20) , 3265-3267
- https://doi.org/10.1200/jco.2009.22.9955
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized TrialsJournal of Clinical Oncology, 2009
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III studyJournal of Clinical Oncology, 2008
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of TreatmentJournal of Clinical Oncology, 2004
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)Journal of Clinical Oncology, 2003
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995